Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
Abstract Background Continuous use of glucocorticoids (GCs) has become the primary cause of secondary osteoporosis. Bisphosphonate drugs were given priority over denosumab and teriparatide in the 2017 American College of Rheumatology (ACR) guidelines but have a series of shortcomings. This study aim...
Main Authors: | Chuanjian Yuan, Yanchen Liang, Kai Zhu, Wenpeng Xie |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | Journal of Orthopaedic Surgery and Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13018-023-03920-4 |
Similar Items
-
Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
by: Toshihiro Nanki, et al.
Published: (2022-12-01) -
USE OF TERIPARATIDE IN SURGICAL PLANNING FOR PATIENTS WITH OSTEOPOROSIS
by: RICARDO CEPEDA JORDAN, et al.
Published: (2023-10-01) -
Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01) -
Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment
by: Mercè Giner, et al.
Published: (2022-08-01) -
Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis
by: Liang Dong, et al.
Published: (2024-01-01)